Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2031567 | 1.00 | TACR1 (0.56) | TACR1CA1CA2CA7CA9 | |
| SCHEMBL82083 | 1.00 | TACR1 (0.56) | TACR1CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL4198860 | 0.98 | TACR1 (0.54) | TACR1CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL4198864 | 0.98 | TACR1 (0.54) | TACR1CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL2444541 | 0.98 | TACR1 (0.54) | TACR1CA1CA2CA7CA9 | |
| SCHEMBL18394417 | 0.88 | TACR1 (0.63) | TACR1CA1CA2CA7CA9 | |
| SCHEMBL7967707 | 0.84 | TACR1 (0.59) | TACR1CA1CA2CA7CA9 | |
| SCHEMBL7965700 | 0.84 | TACR1 (0.59) | TACR1CA1CA2CA7CA9 | |
| SCHEMBL2781643 | 0.84 | TACR1 (0.59) | TACR1CA1CA2CA7CA9 | |
| SCHEMBL18579714 | 0.82 | TACR1 (0.73) | TACR1CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111559980-A | Ornidazole isomer and preparation method thereof | 湖南方盛制药股份有限公司 | 2020-08-21 | — | — | CN | claimed |
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024073587-A1 | N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| CN-117222646-A | KRAS G12C inhibitors and uses thereof | 苏州赞荣医药科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2023040989-A1 | KRAS G12C INHIBITORS AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-03-23 | — | — | WO | disclosed |
| CN-110256418-B | 1, 3-thiazol-2-yl substituted benzamides | 拜耳公司 | 2023-01-20 | — | — | CN | disclosed |
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2022-07-07 | — | — | US | disclosed |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| US-20210087206-A1 | MACROCYCLIC KINASE INHIBITORS AND THEIR USE | TURNING POINT THERAPEUTICS INC (US) | 2021-03-25 | — | — | US | disclosed |
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-04-25 | — | — | US | disclosed |
| US-6355257-B1 | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-03-12 | — | — | US | disclosed |
| US-6303347-B1 | VACCINES | CORIXA CORPORATION | 2001-10-16 | — | — | US | disclosed |
| US-6177562-B1 | Chelated complexes of paramagnetic metals with low toxicity | DIBRA S.P.A. (IT) | 2001-01-23 | — | — | US | disclosed |
| US-6149890-A | 12-CROWN-4-AMINE DERIVATIVE DIAGNOSTIC CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING | DIBRA S.P.A. (IT) | 2000-11-21 | — | — | US | disclosed |
| US-6113918-A | IMMUNOLOGY | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| CN-1265112-A | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors | KRIKSA LTD (US) | 2000-08-30 | — | — | CN | disclosed |
| EP-0872479-A1 | Chelated complexes of paramagnetic metals with low toxicity | BRACCO S.p.A. (IT) | 1998-10-21 | — | — | EP | disclosed |
| EP-0167459-B1 | 2-AMINO OXAZOLINES AND PROCESS FOR THEIR PREPARATION | Albert ROLLAND S.A. Société dite (FR) | 1991-11-06 | — | — | EP | disclosed |
| EP-0167459-A2 | 2-Amino oxazolines and process for their preparation | Albert ROLLAND S.A. Société dite (FR) | 1986-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | MIF, MMP12, SLC11A2 | TACR1 291/4885CA1 2223/4885CA2 708/4885 |
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, TYMS, POLA1 | TACR1 3659/4885CA1 4833/4885CA2 4672/4885 |
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | TACR1 1630/4885CA1 2584/4885CA2 1308/4885 |
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | KEAP1, NFE2L2, NQO1 | TACR1 4613/4885CA1 4860/4885CA2 4545/4885 |
| US-20210087206-A1 | MACROCYCLIC KINASE INHIBITORS AND THEIR USE | MAP3K20, LCK, MAP3K1 | TACR1 3869/4885CA1 2123/4885CA2 1550/4885 |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | TACR1 4519/4885CA1 4811/4885CA2 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.